- Home
- ENLV vs BOLD Comparison
ENLV vs BOLD Comparison
Compare ENLV & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLV | BOLD |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 26.2M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ENLV | BOLD |
|---|---|---|
| Price | $0.83 | $1.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $4.00 |
| AVG Volume (30 Days) | ★ 11.7M | 213.6K |
| Earning Date | 11-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $1.00 |
| 52 Week High | $2.10 | $3.12 |
Technical Indicators
Market Signals| Indicator | ENLV | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 52.63 |
| Support Level | $0.80 | $1.11 |
| Resistance Level | $0.88 | $1.37 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 6.69 | 50.00 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.